Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT03297606
Recruiting
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase 2 · Canada · 10 sites
Registry update: 27 Mar 2026
NCT03717844
Recruiting
Registry for Adults With Plasma Cell Disorders (PCD's)
Not applicable · United States · 1 site
Registry update: 20 Nov 2025
NCT03375619
Recruiting
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Not applicable · United States · 1 site
Registry update: 10 Nov 2025
NCT03308474
Recruiting
Myeloma Registry Platform (MYRIAM)
Not applicable · Germany · 1 site
Registry update: 13 Jul 2026
NCT03702309
Recruiting
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Not applicable · Canada · 1 site
Registry update: 25 Sept 2026
NCT03127761
Recruiting
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Not applicable · United States · 1 site
Registry update: 30 Aug 2023
NCT03017820
Recruiting
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Phase 1 · United States · 2 sites
Registry update: 10 Jun 2026
NCT03131531
Recruiting
Bergamo Lymphoid Cancer Registry
Not applicable · Italy · 1 site
Registry update: 6 Mar 2024
NCT03562169
Recruiting
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
Phase 3 · United Kingdom · 91 sites
Registry update: 19 Jun 2018
NCT03110822
Recruiting
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Phase 1 · United States · 13 sites
Registry update: 1 Nov 2023
NCT03196414
Recruiting
Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
Phase 1/2 · China · 1 site
Registry update: 2 May 2019
NCT02925234
Recruiting
DRUP trial
Phase 2 · Netherlands · 36 sites
Registry update: 20 Aug 2026
NCT05136807
Recruiting
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
Not applicable · United States · 1 site
Registry update: 6 Oct 2026
NCT02727803
Recruiting
Personalized NK Cell Therapy in CBT
Phase 2 · United States · 1 site
Registry update: 2 Nov 2026
NCT02682667
Recruiting
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Not applicable · United States · 1 site
Registry update: 9 Nov 2026
NCT02693535
Recruiting
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Phase 2 · Puerto Rico, United States · 176 sites
Registry update: 22 Sept 2026
NCT02726750
Recruiting
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Not applicable · United States · 1 site
Registry update: 7 Oct 2026
NCT02343042
Recruiting
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Phase 1/2 · Canada, United States · 25 sites
Registry update: 15 Jul 2026
NCT03016806
Recruiting
Umbilical Cord Blood Transplantation From Unrelated Donors
Not applicable · United States · 1 site
Registry update: 10 Oct 2025
NCT02269592
Recruiting
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Not applicable · United States · 7 sites
Registry update: 7 May 2026

Ordered by registry start date. Freshness and sponsorship never change the order.